Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy
Launched by HOSPITAL DE CLINICAS DE PORTO ALEGRE · May 11, 2009
Trial Information
Current as of May 09, 2025
Unknown status
Keywords
ClinConnect Summary
Hepatic encephalopathy continues to be a major clinical problem in cirrhosis. Patients with minimal hepatic encephalopathy are at risk for accidents, had a decline in work performance, or complain of cognitive symptoms, with poor health-related quality of life. This study will compare L-ornithine-L-aspartate with placebo for 60 days to assess the effectiveness, safety and health-related quality of life of this drug.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cirrhosis and diagnosis of minimal hepatic encephalopathy using psychometric tests and critical flicker frequency
- Exclusion Criteria:
- • Hepatic encephalopathy grade 1 to 4
- • Use of drugs to treatment of hepatic encephalopathy (lactulose, neomycin)
- • Psychoactive substance use within 72 hours
About Hospital De Clinicas De Porto Alegre
Hospital de Clínicas de Porto Alegre (HCPA) is a leading academic medical center in Brazil, renowned for its commitment to advancing healthcare through innovative clinical research. As a sponsor of clinical trials, HCPA leverages its extensive expertise in various medical disciplines to conduct rigorous studies aimed at improving patient outcomes and contributing to the global medical community. With a multidisciplinary team of skilled professionals and state-of-the-art facilities, HCPA fosters a collaborative environment that prioritizes ethical standards, patient safety, and scientific integrity in all its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Porto Alegre, Rio Grande Do Sul, Brazil
Patients applied
Trial Officials
Mário R Álvares-da-Silva, PhD
Principal Investigator
Hospital de Clínicas de Porto Alegre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials